Effects of myostatin on muscular function, length of ICU stay and mortality in patients with myocardial infarction with ST-segment elevation

• Grant number: 18/20797-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): June 01, 2019
• Effective date (End): May 31, 2020
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Marcos Ferreira Minicucci
• Grantee: Juliana Faraco Schwed
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Cardiovascular diseases, mainly ischemic heart diseases, are nowadays the major cause of mortality worldwide. In this scenario, several factors are associated with worse prognosis, including muscle mass and strength. Both muscle mass and strength are regulated by myostatin. Myostatin, also known as growth-differentiation factor 8 (GDF-8), belongs to TGF-² family, and is responsible for downregulation of skeletal muscle growth, since embryonic period. Myostatin is associated with muscle mass reduction because it inhibit myogenic regulatory factors and increases muscle breakdown, through ubiquitin/proteasome pathway. Several studies already showed an inverse correlation between myostatin values and muscle mass, suggesting a role of myostatin in heart failure, cirrhosis and cancer related cachexia. Despite the regulatory effect of myostatin in skeletal muscle mass, its association with prognosis in acute coronary syndrome was not yet evaluated. Thus, the objective of our study was to evaluate the effects of serum myostatin values with muscle mass and function, length of ICU stay and mortality in patients with myocardial infarction with ST-segment elevation admitted in coronary ICU and cardiac emergency room.